Is there any good data on Glucagon levels right after dosing various GLP1s?

I keep running into the same gap and wonder whether the popular explanations are simply mixing up cause and effect. At the simplest level the agonist should create a false high-glucagon signal somewhere in the gut or brain, which then changes how much glucagon the body itself releases. The open question is whether that signal ultimately raises or lowers endogenous glucagon output. The retatrutide chart shows a clear drop after the shot, which already conflicts with the usual “more glucagon equals more fat burning” line.

Most commentators know the names of the hormones but have not tried to connect them into a full sequence. That produces statements such as “GLP-1s lower blood sugar by raising insulin,” which is the same description given for sulfonylureas. In reality GLP-1 drugs ultimately reduce insulin needs through weight loss, so the first-order claim is misleading.

The first GLP-1 compounds were developed from the observation that something rises after eating and might fool the brain into thinking a meal has occurred. Later molecules simply added other metabolic hormones in varying ratios, tested them in animals, and moved the best weight-loss candidates forward without a complete mechanistic map. Unlike metformin, where uncertainty was openly acknowledged for years, newer drugs are given simple stories for marketing reasons.

The paper itself states that retatrutide produces larger reductions in fasting glucagon than GLP-1 receptor agonists alone. The comparison numbers may mix short-term and longer-term measurements, but the authors clearly present greater glucagon lowering as an advantage. That directly contradicts the influencer claim that retatrutide works by raising glucagon.

Lower glucagon should in principle reduce both glucose and fat release, yet the body still functions. The real advantage may be greater metabolic flexibility: with lower baseline demands on both insulin and glucagon, the system can adjust more quickly when needed. A study in type-1 diabetic mice showed that lowering glucagon alone allowed the remaining insulin to keep glucose normal.

The review is well written and places the current drugs in historical context. One section refers to “adding glucagon back in” and cites retatrutide as the example, yet the trial data show retatrutide lowers measured glucagon more than GLP-1 agonists. The wording may be loose; the agonist can still activate receptors even while actual circulating glucagon falls.

The talk gives a clear overview. Bikman’s earlier material on the insulin-to-glucagon ratio is also useful background, especially the point that a pure protein meal raises both insulin and glucagon so that blood glucose stays stable.

Having trouble opening the link that was posted earlier. Could it be shared again?

True ketosis is simply measurable ketone production, usually tracked by blood BHB. Retatrutide can support reaching that state but does not guarantee it at lower doses, based on personal observation.

Reposting the resource here for you.